Catalys Pacific

In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After examining hundreds of potential investment opportunities, his team must decide which deals to pursue first. How can Catalys Pacific establish a positive investment track record while galvanizing an entire innovation ecosystem? To achieve its vision, the Catalys Pacific team must use its experience in the Japanese pharmaceutical industry to identify promising deals, while navigating corporate politics and potential cultural roadblocks.